The European Medicines Agency is reviewing the safety of three medicines used for the treatment of weight loss and type 2 diabetes in light of reports from the Icelandic Medicines Agency of suicidal thoughts and attempted self-injury amongst patients taking the drugs. The review will focus on the glucagon-like peptide 1 (GLP-1) receptor agonists liraglutide (Saxenda) and semaglutide (Ozempic and Wegovy), all three of which have been developed by Novo Nordisk A/S. The investigation will involve an analysis of 150 reports of possible self-harm and suicidal thoughts.
